2,527products in the catalogue
2,367EU-authorised medicines (EMA)
160FDA approvals
5 yrsforecast horizon, 2027–2031
Free report
The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Two ways to buy
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
€1,250 per product
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
€4,950 5 products
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
from €4,500
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
What is in every report
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Catalogue
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Afiveg aflibercept BiosimilarAdditional monitoring | STADA Arzneimittel AG | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2025-08-18 | Order → |
| Mynzepli aflibercept BiosimilarAdditional monitoring | Advanz Pharma Limited | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2025-08-18 | Order → |
| Rezdiffra resmetirom ConditionalAdditional monitoring | Madrigal Pharmaceuticals EU Limited | Non-alcoholic Fatty Liver Disease; Liver Cirrhosis | 🇪🇺 EU 2025-08-18 | Order → |
| Vivlipeg pegfilgrastim BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Neutropenia; Febrile Neutropenia; Chemotherapy-Induced Febrile Neutropenia; Cancer | 🇪🇺 EU 2025-08-18 | Order → |
| Eiyzey aflibercept BiosimilarAdditional monitoring | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2025-08-14 | Order → |
| Ogsiveo nirogacestat OrphanAdditional monitoring | Merck Europe B.V. | Desmoid Tumors | 🇪🇺 EU 2025-08-14 | Order → |
| Usymro ustekinumab BiosimilarAdditional monitoring | Gedeon Richter Plc. | Crohn Disease; Psoriasis; Arthritis, Psoriatic | 🇪🇺 EU 2025-08-14 | Order → |
| Vgenfli aflibercept BiosimilarAdditional monitoring | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2025-08-14 | Order → |
| Maapliv amino acids OrphanExceptional circumstances | Recordati Rare Diseases | Maple Syrup Urine Disease | 🇪🇺 EU 2025-07-28 | Order → |
| Riulvy tegomil fumarate GenericAdditional monitoring | Neuraxpharm Pharmaceuticals S.L. | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2025-07-28 | Order → |
| Blenrep belantamab mafodotin Additional monitoring | GlaxoSmithKline Trading Services Limited | Multiple Myeloma | 🇪🇺 EU 2025-07-23 | Order → |
| Conexxence denosumab Biosimilar | Fresenius Kabi Deutschland GmbH | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption | 🇪🇺 EU 2025-07-18 | Order → |
| Emtricitabine / Tenofovir alafenamide Viatris emtricitabine;tenofovir alafenamide Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2025-07-18 | Order → |
| Itovebi inavolisib Additional monitoring | Roche Registration GmbH | Breast Neoplasms | 🇪🇺 EU 2025-07-18 | Order → |
| Attrogy diflunisal | Purpose Pharma International AB | Amyloid Neuropathies, Familial | 🇪🇺 EU 2025-07-17 | Order → |
| Aucatzyl obecabtagene autoleucel PRIMEATMPConditional | Autolus GmbH | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2025-07-17 | Order → |
| Bomyntra denosumab Biosimilar | Fresenius Kabi Deutschland GmbH | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-07-17 | Order → |
| Ezmekly mirdametinib OrphanConditionalAdditional monitoring | Merck Europe B.V. | Neurofibromatosis 1; Neurofibroma, Plexiform | 🇪🇺 EU 2025-07-17 | Order → |
| Rolcya denosumab BiosimilarAdditional monitoring | Sandoz GmbH | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption | 🇪🇺 EU 2025-07-17 | Order → |
| Alyftrek deutivacaftor / tezacaftor / vanzacaftor OrphanAdditional monitoring | Vertex Pharmaceuticals (Ireland) Limited | Cystic Fibrosis | 🇪🇺 EU 2025-06-30 | Order → |
Order
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.